Please update your Flash Player to view content.

Upcoming Events:

There are no upcoming events.

Bio Pro Classes:

 
Thursday, 24 Apr 2014 - Friday, 25 Apr 2014
Category: Bio Pro Classes

 
Thursday, 08 May 2014
Category: Bio Pro Classes

 
Friday, 16 May 2014
Category: Bio Pro Classes

 
Thursday, 22 May 2014
Category: Bio Pro Classes

 
Thursday, 05 Jun 2014 - Friday, 06 Jun 2014
Category: Bio Pro Classes

 
Thursday, 19 Jun 2014 - Friday, 20 Jun 2014
Category: Bio Pro Classes

 
Tuesday, 08 Jul 2014 - Wednesday, 09 Jul 2014
Category: Bio Pro Classes

 
Thursday, 17 Jul 2014 - Friday, 18 Jul 2014
Category: Bio Pro Classes

 
Tuesday, 09 Sep 2014 - Wednesday, 05 Nov 2014
Category: Bio Pro Classes

 
Tuesday, 09 Sep 2014 - Wednesday, 17 Dec 2014
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

Registration now open!

BioForum: ISPE and Oregon Bio at Genentech

Genentech exteriorThe Oregon Bioscience Association has teamed up with the Pacific Northwest Chapter of the International Society for Pharmaceutical Engineering (ISPE) and Genentech to bring you this exciting event - a first of its kind.  Join us to tour the Hillsboro Technical Operations (HTO) facility and learn about the latest innovations in aseptic processing, automated inspection, packaging and serialization, and more.  There will be ample opportunity for networking and learning more about the Oregon Bioscience Association and ISPE.ISPE 2010 PacificNW Chtr cropped

When: Thursday May 8, 2014, 6-9 p.m.
Where: Genentech Hillsboro, 4625 NW Brookwood Parkway, Hillsboro OR 97124
Admission: $45 Members, $70 Non-members, $15 Students

  • Attendees must present a government issued photo ID upon arrival at the event. 
    Entry will not be allowed without a valid ID.
  • Parking is available in paved lots in front of Genentech;
    additional parking is available in the gravel lot off of Evergreen Parkway. 
  • Registration will close on May 5th.  Space is limited, so register today.

Agenda:
6:00 – 6:30: Networking and registration
6:30 – 7:30: Formal presentations
7:30 – 9:00: Open house/window tour and networking

  Sponsorship opportunities available!
  Please contact Julie Black at This email address is being protected from spambots. You need JavaScript enabled to view it. for more information 

Register Now button 

 

 Thanks to our sponsors:

Gold Level:  

      
 

 
 Genentech logo 4-21-14

Silver Level:

 Bronze Level:

CAI Logo  Harris-Group-Logo Blue

News Flash

  • DesignMedix awarded $3 million to develop low-cost, safe malaria drug

    Portland, Oregon, April 15, 2014 — DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.

    “Each year, over 600,000 children under the age of five die of malaria,” said Dr. Sandra Shotwell, president and COO of DesignMedix. “Our new drug will provide another weapon to target this deadly disease, which kills more young children than any other.”

    The drug in development is as a low cost cure for drug-resistant malaria that is as safe as chloroquine, a frontline drug that used for many years until rendered ineffective by drug resistance. Malaria drug resistance — widespread in Africa and Asia — is created by a mutation that causes rapid transport of the drug out of the malaria cells, rendering the drug ineffective. The DesignMedix technology approach creates a new drug that inhibits the transport and overcomes the drug resistance.

    DesignMedix will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company. Three patents have been issued relating to the drug molecules, and DesignMedix has exclusive rights to develop the technology.

    “I am very pleased that NIH has continued to support this work in such a significant way,” said Peyton, who has been working on malaria for more than 15 years.

    Several malaria drugs currently are available from large multinational and Indian drug manufacturers. Most current therapies show drug resistance, and some cost up to tenfold more than the cost projected for DesignMedix’s drug. This drug has high potential to be a good partner drug for existing or pipeline malaria drugs to both overcome drug resistance, and reduce cost. DesignMedix has partnered with Oregon Consultants Inc. (OCI) of Eugene, Oregon to produce material for preclinical and clinical studies.

     About DesignMedix Inc.

    DesignMedix, Inc was founded in 2008 to develop drugs to overcome drug resistance. The company’s initial focus is on oral drugs to treat malaria, which kills over 600,000 people per year and affects up to 500 million people. The company has developed a series of novel, safe and effective drugs that have the potential for low-cost production. For more information please visit http://www.designmedix.com

    The Advanced Technology Phase II award from the National Institutes and Allergy and Infectious Disease (NIAID) is part of the Small Business Technology Transfer Program of the NIH. Research reported in this release is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, under Award Number R41AI094959. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Bioscience News

  • Today is one of the most important office holidays of the year: Administrative Professionals Day. On this day, we take the time to celebrate and thank the hardworking professionals who help keep the trains running on time. Administrative workers handle some of the most important tasks in any office – like booking travel for the BIO International Convention. I know that navigating the Convention is certainly easier with the aid of my Executive Assistant, Kristina, who Read More >

  • Did you know that 1 in 8 couples struggle to have children and build their families due to the disease of infertility? This statistic represents a colleague, a friend in your book club, a couple at your Thanksgiving dinner table. Having infertility can feel embarrassing and isolating, but you can help your friends feel less misunderstood and alone by resolving to know more about infertility this week, during National Infertility Awareness Week®. This year marks the Read More >

  • Today, FasterCures hosted a webinar to discuss how reimbursement decisions impact innovations needed to improve health. The discussion helped provide the medical research community with a fundamental understanding of the evolving coverage landscape. An expert panel outlined the basics of health care plan coverage policies, alternative payment models and evidence-based performance measurements. Margaret Anderson, Executive Director of FasterCures, kicked off the webinar by posing two critical questions – who should determine value and what should inform these decisions? Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2012. All Rights Reserved.